Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 73, Issue 7

Apramycin has high activity against No Access

Abstract

Aminoglycoside antibiotics such as amikacin and kanamycin are important components in the treatment of (Mtb) infection. However, more and more clinical strains are found to be aminoglycoside antibiotic-resistant. Apramycin is another kind of aminoglycoside antibiotic that is commonly used to treat infections in animals.

Apramycin may have activity against Mtb.

This study aims to evaluate the efficacy of apramycin against Mtb and determine its epidemiological cut-off (ECOFF) value.

One hundred Mtb isolates, including 17 pansusceptible and 83 drug-resistant tuberculosis (DR-TB) strains, were analysed for apramycin resistance using the MIC assay.

Apramycin exhibited significant inhibitory activity against Mtb clinical isolates, with an MIC of 0.5 μg ml and an MIC of 1 μg ml. We determined the tentative ECOFF value as 1 µg ml for apramycin. The resistant rates of multidrug-resistant tuberculosis (MDR-TB), pre-extensively drug-resistant (pre-XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains were 12.12 % (4/33), 20.69 % (6/29) and 66.67 % (14/21), respectively. The gene A1401G is associated with apramycin resistance, as well as the cross-resistance between apramycin and other aminoglycosides.

Apramycin shows high activity against the Mtb clinical isolates, especially the MDR-TB clinical isolates. This encouraging discovery calls for more research on the functions of apramycin and as a possible antibiotic for the treatment of drug-resistant TB.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): aminoglycosides , apramycin , ECOFF , MIC , multidrug-resistant tuberculosis and Mycobacterium tuberculosis
Funding
This study was supported by the:
  • Beijing Public Health Experts Project (Award 2022-3-040)
© 2024 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001854
2024-07-08
2025-05-19
Loading full text...

Full text loading...

References

  1. WHO Global tuberculosis report; 2023
  2. Walker TM, Miotto P, Köser CU, Fowler PW, Knaggs J et al. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe 2022; 3:e265–e273 [View Article] [PubMed]
     [Google Scholar]
  3. Ernest JP, Sarathy J, Wang N, Kaya F, Zimmerman MD et al. Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis. Antimicrob Agents Chemother 2021; 65:e0050621 [View Article] [PubMed]
     [Google Scholar]
  4. Xu Z, Xu X, Qi D, Yang L, Li B et al. Effect of aminoglycosides on the pathogenic characteristics of microbiology. Microb Pathog 2017; 113:357–364 [View Article] [PubMed]
     [Google Scholar]
  5. Islam MM, Tan Y, Hameed HMA, Liu Y, Chhotaray C et al. Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China. J Glob Antimicrob Resist 2020; 22:290–295 [View Article] [PubMed]
     [Google Scholar]
  6. Sabur NF, Brar MS, Wu L, Brode SK. Low-dose amikacin in the treatment of multidrug-resistant tuberculosis (MDR-TB). BMC Infect Dis 2021; 21:254 [View Article] [PubMed]
     [Google Scholar]
  7. Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G et al. Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. Antimicrob Agents Chemother 2015; 59:6337–6343 [View Article] [PubMed]
     [Google Scholar]
  8. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38:1538–1544 [View Article] [PubMed]
     [Google Scholar]
  9. Hao M, Shi X, Lv J, Niu S, Cheng S et al. In vitro activity of apramycin against carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates. Front Microbiol 2020; 11:425 [View Article] [PubMed]
     [Google Scholar]
  10. Hao M, Schuyler J, Zhang H, Shashkina E, Du H et al. Apramycin resistance in epidemic carbapenem-resistant Klebsiella pneumoniae ST258 strains. J Antimicrob Chemother 2021; 76:2017–2023 [View Article]
     [Google Scholar]
  11. Juhas M, Widlake E, Teo J, Huseby DL, Tyrrell JM et al. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii. J Antimicrob Chemother 2019; 74:944–952 [View Article] [PubMed]
     [Google Scholar]
  12. Di Bonaventura G, Lupetti V, Verginelli F, Giancristofaro S, Barbieri R et al. Repurposing the veterinary antibiotic apramycin for antibacterial and antibiofilm activity against Pseudomonas aeruginosa from cystic fibrosis patients. Front Microbiol 2021; 12:801152 [View Article] [PubMed]
     [Google Scholar]
  13. Moore JE, Koulianos G, Hardy M, Misawa N, Millar BC. Antimycobacterial activity of veterinary antibiotics (Apramycin and Framycetin) against Mycobacterium abscessus: Implication for patients with cystic fibrosis. Int J Mycobacteriol 2018; 7:265–267 [View Article] [PubMed]
     [Google Scholar]
  14. Nguyen M-VH, Daley CL. Treatment of Mycobacterium avium complex pulmonary disease: when should I treat and what therapy should I start?. Clin Chest Med 2023; 44:771–783 [View Article] [PubMed]
     [Google Scholar]
  15. Sun Q, Liao X, Wang C, Jiang G, Yang J et al. In vitro activity of fidaxomicin against nontuberculosis mycobacteria. J Med Microbiol 2022; 71: [View Article] [PubMed]
     [Google Scholar]
  16. Sun Q, Liao X, Yan J, Jiang G, Huo F et al. In vitro activity of tubercidin against Mycobacterium tuberculosis and nontuberculosis Mycobacteria. J Med Microbiol 2023; 72: [View Article]
     [Google Scholar]
  17. Sun Q, Wang S, Liao X, Jiang G, Huang H et al. Fidaxomicin has high in vitro activity against Mycobacterium tuberculosis. J Med Microbiol 2021; 70: [View Article]
     [Google Scholar]
  18. Huang H, Ding N, Yang T, Li C, Jia X et al. Cross-sectional whole-genome sequencing and epidemiological study of multidrug-resistant Mycobacterium tuberculosis in China. Clin Infect Dis 2019; 69:405–413 [View Article] [PubMed]
     [Google Scholar]
  19. Ramirez MS, Tolmasky ME. Amikacin: uses, resistance, and prospects for inhibition. Molecules 2017; 22:2267 [View Article] [PubMed]
     [Google Scholar]
  20. Tsai A, Uemura S, Johansson M, Puglisi EV, Marshall RA et al. The impact of aminoglycosides on the dynamics of translation elongation. Cell Rep 2013; 3:497–508 [View Article] [PubMed]
     [Google Scholar]
  21. Becker K, Cao S, Nilsson A, Erlandsson M, Hotop S-K et al. Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis. EBioMedicine 2021; 73:103652 [View Article] [PubMed]
     [Google Scholar]
  22. Matt T, Ng CL, Lang K, Sha S-H, Akbergenov R et al. Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci U S A 2012; 109:10984–10989 [View Article] [PubMed]
     [Google Scholar]
  23. Meyer M, Freihofer P, Scherman M, Teague J, Lenaerts A et al. In vivo efficacy of apramycin in murine infection models. Antimicrob Agents Chemother 2014; 58:6938–6941 [View Article] [PubMed]
     [Google Scholar]
  24. Sugawara I, Zhang J, Li C. Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin. Indian J Exp Biol 2009; 47:520–522 [PubMed]
     [Google Scholar]
  25. Wei W, Zhao Y, Zhang C, Yu M, Wu Z et al. Whole-genome sequencing and transcriptome-characterized in vitro evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Microb Genom 2023; 9:mgen001022 [View Article] [PubMed]
     [Google Scholar]
  26. Selchow P, Ordway DJ, Verma D, Whittel N, Petrig A et al. Apramycin overcomes the inherent lack of antimicrobial bactericidal activity in Mycobacterium abscessus. Antimicrob Agents Chemother 2022; 66:e0151021 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001854
Loading
Apramycin has high in vitro activity against Mycobacterium tuberculosis
J. Med. Microbiol. 73, 001854 (2024); https://doi.org/10.1099/jmm.0.001854
/content/journal/jmm/10.1099/jmm.0.001854
/content/journal/jmm/10.1099/jmm.0.001854
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error